Bharat Biotech released the final result Bharat Biotech today released the final results of the Phase III trial of Covaxin. Bharat Biotech has completed the final analysis of the results of the Phase III trial of indigenous corona vaccine Covaxin. Bharat Biotech concluded the final analysis for the efficacy of Covaccine as part of Phase III trials after evaluating 130 confirmed cases. Covaxin has been found to be 77.8 percent effective on corona-infected patients with symptoms. According to the final analysis, the trial of Covaccine was done at 25 trial centers in the country. It was attended by 25,800 volunteers in the age group of 18 to 98 years.
Also Read: SECURITY FORCES HAVE KILLED 66 EXTREMISTS IN THE VALLEY SINCE JANUARY
What else was found in the final analysis?
Many important things have come to light in the final analysis of the results
Bharat Biotech released the final result A week before this, Bharat Biotech’s Covaxin was found to be 77.8 percent effective in the third phase of the trial. The Subject Expert Committee (SEC) of the Indian drug regulator reviewed the Phase III trial of the vaccine. Bharat Biotech is a Hyderabad-based company. It submitted data from the Phase III trial of Covaccine to the Drug Controller General of India over the weekend. Questions were raised on several occasions regarding the data of the Phase III trial of Covaccine. This is why the company’s data on the effectiveness of the vaccine is important.
Three vaccines being launched in India
Currently, three vaccines are being used against corona in India. Bharat Biotech’s Covaccine is also one of them. This is an indigenous vaccine made in the country. The second vaccine Kovishield is being applied. It has been made by the University of Oxford and AstraZeneca. It is locally produced by Serum Institute of India. Apart from this, Russia’s Sputnik-V vaccine is also being installed. Bharat Biotech has developed Covaccine in collaboration with the Indian Council of Medical Research. This is the first indigenous vaccine made in India.
On the other hand, Bharat Biotech has had a meeting with the World Health Organization (WHO) to get the vaccine internationally approved.
